C12N 2710/10034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/10034 (Use of virus or viral component as vaccine) appears on 72 US grants and 138 published applications in this corpus.
Search patents in C12N- Granted patents
- 72
- Published applications
- 138
- Assignees
- 99
- Inventors
- 287
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 1 | 0 |
| 2010 | 1 | 5 |
| 2011 | 0 | 2 |
| 2012 | 1 | 2 |
| 2013 | 1 | 5 |
| 2014 | 0 | 8 |
| 2015 | 1 | 10 |
| 2016 | 6 | 9 |
| 2017 | 5 | 7 |
| 2018 | 8 | 12 |
| 2019 | 7 | 13 |
| 2020 | 3 | 9 |
| 2021 | 7 | 12 |
| 2022 | 14 | 11 |
| 2023 | 4 | 7 |
| 2024 | 3 | 5 |
| 2025 | 6 | 10 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- IL-10 inhibition for vaccines and immunotherapy24 Feb 2026US 12,558,413 B2The Regents of the University of California
- Methods and compositions for producing an adenovirus vector for use with multiple vaccinations29 Jul 2025US 12,370,250 B2Etubics Corporation
- Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy8 Jul 2025US 12,350,375 B2Leukocare AG
- IL-2 superagonists in combination with anti-PD-1 antibodies24 Jun 2025US 12,338,269 B2Medicenna Therapeutics Inc.
- Hepatitis C virus immunogenic compositions and methods of use thereof13 May 2025US 12,296,005 B2The Governors of the University of Alberta
- Protein and vaccine against infection by sars-cov-2 omicron variant strain and subtype thereof10 Sep 2026US 2026/0263587 A1Westvac Biopharma Co., Ltd.
- Adenoviral vector vaccine, and preparation method and use thereof10 Sep 2026US 2026/0265702 A1Cansino Biologics Inc.
- Pharmaceutical composition for resisting infection with sars-cov-2 or mutant thereof, and combined drug thereof12 Feb 2026US 2026/0041761 A1Westvac Biopharma Co., Ltd.
- Process for t cell expansion12 Feb 2026US 2026/0042987 A1AlloVir, Inc.
- Il-2 superagonists in combination with anti-pd-1 antibodies5 Feb 2026US 2026/0035427 A1Medicenna Therapeutics Inc.
Most cited
By later US patents
- VISTA modulators for diagnosis and treatment of cancer37US 9,381,244 B2King's College London · 2016
- Selective cell targeting using adenovirus and chemical dimers24US 9,913,866 B2The Salk Institute for Biological Studies · 2018
- Inactivated canine coronavirus vaccine22US 4,567,042 AAmerican Home Products Corporation · 1986
- Recombinant serotype 5 (Ad5) adenoviral vectors16US 9,410,129 B2Targovax Oy · 2016
- Sequential administration of a replication defective adenovirus vector in vaccination protocols15US 8,298,549 B2Etubics Corporation · 2012